InvestorsHub Logo
Followers 84
Posts 32292
Boards Moderated 85
Alias Born 03/22/2005

Re: gfp927z post# 617

Thursday, 01/04/2024 9:23:26 PM

Thursday, January 04, 2024 9:23:26 PM

Post# of 654
>>> Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference


PR Newswire

January 3, 2024


https://finance.yahoo.com/news/acurx-present-42nd-annual-j-130000189.html


STATEN ISLAND, N.Y., Jan. 3, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") today announced that President and Chief Executive Officer David P. Luci will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm PST. An audio webcast of the presentation will be available live at https://jpmorgan.metameetings.net/events/healthcare24/sessions/50099-acurx-pharmaceuticals-inc/webcast?gpu_only=true&kiosk=true and will be available upon completion of the conference on the Company's website at www.acurxpharma.com under the Investors section.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

<<<



---

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.